Seller record · Telehealth service

Fitish

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 2 of 8 criteria. S3, pharmacy identification: The site names no filling pharmacy. The product pages say only a state licensed sterile compounding pharmacy, and the telehealth consent refers to pharmacy partners without naming one. 1 more criterion also fails; see the table below.

At a glance

FitishTelehealth service

6/8criteria passed

Price: Semaglutide $219 a month, tirzepatide $339
Sells: compounded semaglutide with B6, compounded tirzepatide, and 7 more
FDA letters: 1 on file

Visit Fitish See all eight dispositions

Telehealth service. Passes 6 of 8 criteria. Recorded against Standard v1.1.

A clean beauty brand with a telehealth clinic selling compounded semaglutide and tirzepatide, a GLP-1 microdose program, oral tirzepatide tablets, sermorelin, NAD+ and GHK-Cu, each at a monthly price. An FDA warning letter of June 2026 names it over claims about its compounded GLP-1 drugs.

Operating entity Fitish, LLC

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Fitish's compounded semaglutide product page; Fitish's telehealth consent page
S2	Prescription gating	PASS	Fitish's intake page on its try storefront; Fitish's compounded semaglutide product page
S3	Pharmacy identification	FAIL	Fitish's compounded semaglutide product page; Fitish's telehealth consent page; Fitish's fda disclosure page
S4	Compounding disclosure	PASS	Fitish's compounded semaglutide product page; Fitish's fda disclosure page
S5	Analytical documentation	FAIL	Fitish's certificate quality assurance page
S6	Business address	PASS	Fitish's privacy policy; Fitish's telehealth consent page
S7	Price disclosure	PASS	Fitish's compounded semaglutide product page; Fitish's compounded tirzepatide product page; Fitish's sermorelin product page; Fitish's NAD+ product page
S8	Enforcement status	PASS	fda.gov; letter 728280

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed provider reviews every intake and writes the prescription only if the drug is a fit, and the telehealth consent says consultations are done through DrTelx.Source: Fitish's compounded semaglutide product page; Fitish's telehealth consent page.

S2PASSEvery start button opens a medical intake whose first question asks the primary health goal, and the prescription products carry no cart.Source: Fitish's intake page on its try storefront; Fitish's compounded semaglutide product page.

S3FAILThe site names no filling pharmacy. The product pages say only a state licensed sterile compounding pharmacy, and the telehealth consent refers to pharmacy partners without naming one.Source: Fitish's compounded semaglutide product page; Fitish's telehealth consent page; Fitish's fda disclosure page.

S4PASSCompounded medications are not FDA-approved and do not undergo FDA review for safety, effectiveness, or manufacturing quality, printed on every prescription product page and repeated on the FDA disclosure page.Source: Fitish's compounded semaglutide product page; Fitish's fda disclosure page.

S5FAILNo certificate of analysis is published for any prescription product. The certificate page covers the hemp in the skincare line only.Source: Fitish's certificate quality assurance page.

S6PASSFitish, LLC at 2311 East Loop 820 North, Fort Worth, Texas 76118, printed in the privacy policy and the telehealth consent. The contact page gives only email addresses.Source: Fitish's privacy policy; Fitish's telehealth consent page.

S7PASSCompounded semaglutide at $219 for a monthly supply and compounded tirzepatide at $339, with the microdose program at $179, oral tirzepatide at $339, sermorelin at $149, the NAD+ injection at $219, NAD+ nasal spray at $149, GHK-Cu cream at $150 and GHK-Cu tablets at $189.Source: Fitish's compounded semaglutide product page; Fitish's compounded tirzepatide product page; Fitish's sermorelin product page; Fitish's NAD+ product page.

S8PASSFDA warning letter 728280, June 2026, names FITISH at Fitish's website and alleges that its claims about compounded semaglutide and tirzepatide are false or misleading, among them a pictured label naming FITISH as the compounder and the statement that semaglutide is the active ingredient in Ozempic. No FDA action has halted the business, and the storefront still trades.Source: fda.gov; letter 728280.

Products shown on the seller's own pages at the recorded date: compounded semaglutide with B6, compounded tirzepatide, compounded oral tirzepatide tablets, GLP-1 microdosing program, sermorelin, NAD+ injection and nasal spray, GHK-Cu face cream and oral tablets, MIC B12, skincare.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide Who sells sermorelin Who sells NAD+Who sells GHK-Cu

Enforcement documents on file: 1 warning letter

FDA warning letter 728280, issued June 2026, to FITISHPictured labels identify FITISH as the compounder of semaglutide and tirzepatide products when it is not, and the site claims the same active ingredient as the brand medications Ozempic, Mounjaro and Zepbound.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Unpaid link. Fitish does not pay the site, and nothing is earned when it is used. Funding.

Visit Fitish

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.